Benjamin Halladay - Mar 14, 2023 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role: Chief Financial Officer
Signature: /s/ Sheldon L. Koenig, by power of attorney
Stock symbol: ESPR
Transactions as of: Mar 14, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/15/2023, 09:21 AM
Previous filing: Dec 12, 2022
Next filing: Mar 15, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ESPR	Common Stock	Award	$0	+9.2K	+14.21%	$0.00	73.9K	Mar 14, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ESPR	Stock Option (right to buy)	Award	$0	+39K		$0.00	39K	Mar 14, 2023	Common Stock	39K	$4.02	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Such award will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service.
F2	Consists of 73,936 shares of common stock held, including 2,306 shares recently acquired in Esperion's Employee Stock Purchase Plan.
F3	Such options will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service.